Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicentre, Randomised, Double-blinded, Placebo-controlled, Multi-dose and Multi-injection, Parallel Groups Study to Evaluate the Efficacy and the Safety of Ovasave in Patients With Active Refractory Crohn's Disease

NCT02327221 is registered in ClinicalTrials.gov with TxCell as lead sponsor.

NCT NCT02327221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02327221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicentre, Randomised, Double-blinded, Placebo-controlled, Multi-dose and Multi-injection, Parallel Groups Study to Evaluate the Efficacy and the Safety of Ovasave in Patients With Active Refractory Crohn's Disease
Lead sponsor
TxCell
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2014
Completion date
November 30, 2016
Enrollment
32 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease